This supports the notion that immune dysfunction associated with co-expression of inhibitory receptors on CD8+ T cells can be reversed (32, 33) and that the robust expansion of CD8+PD-1+ T cells may predict clinical benefit from ACT. The gene discussed is PDCD1; the disease is immune system disorder.